SLC19A1 pharmacogenomics summary

Pharmacogenetics and Genomics

Volumn 20, Issue 11, 2010, Pages 708-715

  Yee, Sook Wah ^a   Gong, Li ^b   Badagnani, Ilaria ^a   Giacomini, Kathleen M ^a   Klein, Teri E ^b   Altman, Russ B ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID; GENOMIC DNA; GW 1843; METHOTREXATE; NICOTINAMIDE METHYLTRANSFERASE; PEMETREXED; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; BONE MARROW TOXICITY; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; DRUG MEGADOSE; ESOPHAGUS CANCER; FOLIC ACID BLOOD LEVEL; GASTROINTESTINAL TOXICITY; GENE FREQUENCY; GENE INTERACTION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEOPLASM; NEURAL TUBE DEFECT; NONHODGKIN LYMPHOMA; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPINA BIFIDA; STOMACH CANCER; UTERINE CERVIX CARCINOMA; VITAMIN SUPPLEMENTATION;

EID: 78049285802     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833eca92     Document Type: Review

References (59)

1. Smulders YM, Stehouwer CD. Folate metabolism and cardiovascular disease. Semin Vasc Med 2005; 5:87-97.
2. Prasad PD, Ramamoorthy S, Leibach FH, Ganapathy V. Molecular cloning of the human placental folate transporter. Biochem Biophys Res Commun 1995; 206:681-687.
3. Nguyen TT, Dyer DL, Dunning DD, Rubin SA, Grant KE, Said HM. Human intestinal folate transport: cloning, expression, and distribution of complementary RNA. Gastroenterology 1997; 112:783-791.
4. Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem 1995; 270:17468-17475.
5. Williams FM, Flintoff WF. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J Biol Chem 1995; 270:2987-2992.
6. Dixon KH, Lanpher BC, Chiu J, Kelley K, Cowan KH. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem 1994; 269:17-20.
7. Chiao JH, Roy K, Tolner B, Yang CH, Sirotnak FM. RFC-1 gene expression regulates folate absorption in mouse small intestine. J Biol Chem 1997; 272:11165-11170.
8. Zhao R, Gao F, Goldman ID. Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells. Am J Physiol Cell Physiol 2002; 282:C1512-C1517.
9. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007; 26:111-128.
10. Ifergan I, Jansen G, Assaraf YG. The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis. J Biol Chem 2008; 283:20687-20695.
11. 0 heterogeneity in lymphoblast mRNA. Somat Cell Mol Genet 1998; 24:143-156.
12. 0 end heterogeneity. Gene 1998; 211:331-341.
13. Whetstine JR, Witt TL, Matherly LH. The human reduced folate carrier gene is regulated by the AP2 and sp1 transcription factor families and a functional 61-base pair polymorphism. J Biol Chem 2002; 277:43873-43880.
14. Whetstine JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J 2002; 367:629-640.
15. Patterson D, Graham C, Cherian C, Matherly LH. A humanized mouse model for the reduced folate carrier. Mol Genet Metab 2008; 93:95-103.
16. Tse A, Brigle K, Taylor SM, Moran RG. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate. J Biol Chem 1998; 273:25953-25960.
17. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997; 89:1013-1018.
18. Wong SC, Zhang L, Proefke SA, Hukku B, Matherly LH. Gene amplification and increased expression of the reduced folate carrier in transport elevated K562 cells. Biochem Pharmacol 1998; 55:1135-1138.
19. Wong SC, Zhang L, Witt TL, Proefke SA, Bhushan A, Matherly LH. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 1999; 274:10388-10394.
20. Yang R, Li WW, Hoang BH, Kim H, Banerjee D, Kheradpour A, et al. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. BMC Cancer 2008; 8:124.
21. Charasson V, Hillaire-Buys D, Solassol I, Laurand-Quancard A, Pinguet F, Le Morvan V, Robert J. Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model. Eur J Cancer 2009; 45:2391-2401.
22. Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, Mathew S, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 1999; 93:1643-1650.
23. Kager L, Cheok M, Yang W, Zaza G, Cheng Q, Panetta JC, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005; 115:110-117.
24. Gifford AJ, Haber M, Witt TL, Whetstine JR, Taub JW, Matherly LH, Norris MD. Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells. Leukemia 2002; 16:2379-2387.
25. Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998; 273:30189-30198.
26. Drori S, Jansen G, Mauritz R, Peters GJ, Assaraf YG. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem 2000; 275:30855-30863.
27. Kaufman Y, Ifergan I, Rothem L, Jansen G, Assaraf YG. Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss. Blood 2006; 107:3288-3294.
28. Kaufman Y, Drori S, Cole PD, Kamen BA, Sirota J, Ifergan I, et al. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. Cancer 2004; 100:773-782.
29. Yang R, Sowers R, Mazza B, Healey JH, Huvos A, Grier H, et al. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 2003; 9:837-844.
30. Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfister M, Rosenblatt DS, Nicolas JP. A polymorphism (80G-> A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000; 70:310-315.
31. Devlin AM, Clarke R, Birks J, Evans JG, Halsted CH. Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. Am J Clin Nutr 2006; 83:708-713.
32. Stanislawska-Sachadyn A, Mitchell LE, Woodside JV, Buckley PT, Kealey C, Young IS, et al. The reduced folate carrier (SLC19A1) c.80G>A polymorphism is associated with red cell folate concentrations among women. Ann Hum Genet 2009; 73:484-491.
33. Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RH. Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 2002; 108:1-6.
34. Pei L, Zhu H, Zhu J, Ren A, Finnell RH, Li Z. Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial defects and congenital heart defects in China. Ann Epidemiol 2006; 16:352-356.
35. Whetstine JR, Gifford AJ, Witt T, Liu XY, Flatley RM, Norris M, et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 2001; 7:3416-3422.
36. Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G, et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004; 14:733-739.
37. Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J 2007; 7:404-407.
38. James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol 2008; 35:562-571.
39. Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006; 28:64-68.
40. Collin SM, Metcalfe C, Zuccolo L, Lewis SJ, Chen L, Cox A, et al. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 2009; 18:2528-2539.
41. Lee KM, Lan Q, Kricker A, Purdue MP, Grulich AE, Vajdic CM, et al. One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum Genet 2007; 122:525-533.
42. Lissowska J, Gaudet MM, Brinton LA, Chanock SJ, Peplonska B, Welch R, et al. Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: a population-based case-control study and meta-analyses. Int J Cancer 2007; 120:2696-2703.
43. Wang L, Chen W, Wang J, Tan Y, Zhou Y, Ding W, et al. Reduced folate carrier gene G80A polymorphism is associated with an increased risk of gastroesophageal cancers in a Chinese population. Eur J Cancer 2006; 42:3206-3211.
44. De Jonge R, Tissing WJ, Hooijberg JH, Jansen G, Kaspers GJ, Lindemans J, et al. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood 2009; 113:2284-2289.
45. Zhao R, Assaraf YG, Goldman ID. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J Biol Chem 1998; 273:19065-19071.
46. Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem J 2002; 367:741-750.
47. Rady PL, Szucs S, Matalon RK, Grady J, Hudnall SD, Kellner LH, Nitowsky H. Genetic polymorphism (G80A) of reduced folate carrier gene in ethnic populations. Mol Genet Metab 2001; 73:285-286.
48. De Marco P, Calevo MG, Moroni A, Arata L, Merello E, Cama A, et al. Polymorphisms in genes involved in folate metabolism as risk factors for NTDs. Eur J Pediatr Surg 2001; 11 (Suppl 1):S14-S17.
49. Yates Z, Lucock M. G80A reduced folate carrier SNP modulates cellular uptake of folate and affords protection against thrombosis via a non homocysteine related mechanism. Life Sci 2005; 77:2735-2742.
50. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100:3832-3834.
51. Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, et al. The association of reduced folate carrier 80G > A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 2010; 115:4671-4677.
52. Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109:4151-4157.
53. Figueiredo JC, Levine AJ, Lee WH, Conti DV, Poynter JN, Campbell PT, et al. Genes involved with folate uptake and distribution and their association with colorectal cancer risk. Cancer Causes Control 2010; 21:597-608.
54. 0- flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy. Rheumatol Int 2007; 27:1057-1061.
55. Shen M, Rothman N, Berndt SI, He X, Yeager M, Welch R, et al. Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung Cancer 2005; 49:299-309.
56. Lim U, Wang SS, Hartge P, Cozen W, Kelemen LE, Chanock S, et al. Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study. Blood 2007; 109:3050-3059.
57. Chung HH, Kim MK, Kim JW, Park NH, Song YS, Kang SB, Lee HP. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol 2006; 103:1031-1037.
58. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010; 28:614-619.
59. Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009; 27:5972-5978.